{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:42Z","timestamp":1786979622940,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>\n                    Im Rahmen der aktuellen\n                    <jats:italic>coronavirus disease 2019<\/jats:italic>\n                    (COVID-19)-Pandemie m\u00fcssen sich viele Bereiche der Medizin umstrukturieren. Dies betrifft auch die Versorgung von Patienten mit psychischen Erkrankungen. Die Therapie psychischer Erkrankungen umfasst psychotherapeutische und psychopharmakologische Interventionen. Letztere k\u00f6nnen mit einer Vielzahl an unerw\u00fcnschten Arzneimittelwirkungen (UAW) assoziiert sein, stellen aber in der aktuellen Situation mit Kontakt- und Ausgangsbeschr\u00e4nkungen die pr\u00e4ferierte Therapieoption dar. Da der direkte Patientenkontakt zugunsten des Telefonats oder der Videokonferenz reduziert ist, m\u00fcssen angepasste diagnostische und therapeutische Optionen gefunden werden, um eine ausreichende Patientensicherheit zu gew\u00e4hrleisten. Bedeutend sind hierbei die ausf\u00fchrliche Aufkl\u00e4rung der Patienten sowie eine aktive Abfrage von Symptomen zur rechtzeitigen Erkennung von UAW. Unter der Behandlung mit Psychopharmaka sind UAW zu bef\u00fcrchten, die besonders ung\u00fcnstig sind, wenn sie im Rahmen einer akuten Infektion auftreten oder ein erh\u00f6htes Infektionsrisiko beg\u00fcnstigen. Hierzu geh\u00f6ren Atemdepression, Agranulozytose, Intoxikation durch Hemmung des Arzneistoffmetabolismus und ven\u00f6se Thromboembolien, die jeweils mit potenziell lebensbedrohlichen Folgen einhergehen. Gleichzeitig sollte auf eine ausreichende Wirksamkeit der Medikation geachtet werden, da die gegenw\u00e4rtige Krise zu einer Exazerbation vorbestehender psychischer Erkrankungen f\u00fchren bzw. deren Erstmanifestation beg\u00fcnstigen kann.\n                  <\/jats:p>","DOI":"10.1007\/s00115-020-00939-4","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T07:07:13Z","timestamp":1591081633000},"page":"604-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Psychopharmakotherapie in Zeiten der COVID-19-Pandemie","Psychopharmacotherapy during the COVID-19 pandemic"],"prefix":"10.1007","volume":"91","author":[{"given":"J.","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Eckermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"939_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev.pharmtox.46.120604.141059","volume":"46","author":"AE Aitken","year":"2006","unstructured":"Aitken\u00a0AE, Richardson\u00a0TA, Morgan\u00a0ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123\u2013149","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"939_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir\u00a0JM, Lieberman\u00a0JA, Safferman\u00a0AZ et al (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N\u00a0Engl J Med 329:162\u2013167","journal-title":"N Engl J Med"},{"key":"939_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s40262-016-0400-9","volume":"55","author":"GD Anderson","year":"2016","unstructured":"Anderson\u00a0GD, Chan\u00a0LN (2016) Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet 55:1353\u20131368","journal-title":"Clin Pharmacokinet"},{"key":"939_CR4","first-page":"1","volume":"105","author":"S Battaglia","year":"2014","unstructured":"Battaglia\u00a0S, Bezzi\u00a0M, Sferrazza Papa\u00a0GF (2014) Are benzodiazepines and opioids really safe in patients with severe COPD? Minerva Med 105:1\u20137","journal-title":"Minerva Med"},{"issue":"19","key":"939_CR5","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao\u00a0B, Wang\u00a0Y, Wen\u00a0D et al (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N\u00a0Engl J Med 382(19):1787\u20131799. https:\/\/doi.org\/10.1056\/NEJMoa2001282","journal-title":"N Engl J Med"},{"key":"939_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","volume":"57","author":"A Cortegiani","year":"2020","unstructured":"Cortegiani\u00a0A, Ingoglia\u00a0G, Ippolito\u00a0M et al (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J\u00a0Crit Care 57:279\u2013283. https:\/\/doi.org\/10.1016\/j.jcrc.2020.03.005","journal-title":"J Crit Care"},{"issue":"19","key":"939_CR7","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/eurheartj\/ehaa254","volume":"41","author":"GB Danzi","year":"2020","unstructured":"Danzi\u00a0GB, Loffi\u00a0M, Galeazzi\u00a0G et al (2020) Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart\u00a0J 41(19):1858. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa254","journal-title":"Eur Heart J"},{"key":"939_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0006-2952(98)00372-4","volume":"57","author":"J Elkahwaji","year":"1999","unstructured":"Elkahwaji\u00a0J, Robin\u00a0MA, Berson\u00a0A et al (1999) Decrease in hepatic cytochrome P450 after interleukin\u20112 immunotherapy. Biochem Pharmacol 57:951\u2013954","journal-title":"Biochem Pharmacol"},{"key":"939_CR9","unstructured":"Fachinfo-Service Fachinformationsverzeichnis Deutschland (2020) Webpr\u00e4senz. www.fachinfo.de. Zugegriffen: 21. Apr. 2020"},{"key":"939_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jpainsymman.2017.08.004","volume":"55","author":"M Gol\u010di\u0107","year":"2018","unstructured":"Gol\u010di\u0107\u00a0M, Dobrila-Dintinjana\u00a0R, Gol\u010di\u0107\u00a0G et al (2018) The impact of combined use of opioids, antipsychotics, and anxiolytics on survival in the hospice setting. J\u00a0Pain Symptom Manage 55:22\u201330","journal-title":"J Pain Symptom Manage"},{"key":"939_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016","author":"J Grein","year":"2020","unstructured":"Grein\u00a0J, Ohmagari\u00a0N, Shin\u00a0D et al (2020) Compassionate use of remdesivir for patients with severe Covid-19. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2007016","journal-title":"N Engl J Med"},{"key":"939_CR12","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00213-015-3976-0","volume":"233","author":"G Hefner","year":"2016","unstructured":"Hefner\u00a0G, Shams\u00a0ME, Unterecker\u00a0S et al (2016) Inflammation and psychotropic drugs: the relationship between C\u2011reactive protein and antipsychotic drug levels. Psychopharmacol (Berl) 233:1695\u20131705","journal-title":"Psychopharmacol (Berl)"},{"key":"939_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00228-014-1777-8","volume":"71","author":"M Huber","year":"2015","unstructured":"Huber\u00a0M, Andersohn\u00a0F, Sarganas\u00a0G et al (2015) Metamizole-induced agranulocytosis revisited: results from the prospective Berlin case-control surveillance study. Eur J Clin Pharmacol 71:219\u2013227","journal-title":"Eur J Clin Pharmacol"},{"key":"939_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00134-015-3965-0","volume":"42","author":"JA Klastersky","year":"2016","unstructured":"Klastersky\u00a0JA, Meert\u00a0AP (2016) Understanding the risk for infection in patients with neutropenia. Intensive Care Med 42:268\u2013270","journal-title":"Intensive Care Med"},{"key":"939_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.013","author":"FA Klok","year":"2020","unstructured":"Klok\u00a0FA, Kruip\u00a0M, van der Meer\u00a0NJM et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. https:\/\/doi.org\/10.1016\/j.thromres.2020.04.013","journal-title":"Thromb Res"},{"key":"939_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4088\/JCP.11m07244","volume":"73","author":"L Lahdelma","year":"2012","unstructured":"Lahdelma\u00a0L, Appelberg\u00a0B (2012) Clozapine-induced agranulocytosis in Finland, 1982\u20132007: long-term monitoring of patients is still warranted. J\u00a0Clin Psychiatry 73:837\u2013842","journal-title":"J Clin Psychiatry"},{"key":"939_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.7861\/clinmed.2019-coron","volume":"20","author":"MA Lake","year":"2020","unstructured":"Lake\u00a0MA (2020) What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond) 20:124\u2013127","journal-title":"Clin Med (Lond)"},{"key":"939_CR18","doi-asserted-by":"publisher","DOI":"10.1159\/000507638","author":"J de Leon","year":"2020","unstructured":"de Leon\u00a0J, Ruan\u00a0CJ, Schoretsanitis\u00a0G et\u00a0al (2020) A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. https:\/\/doi.org\/10.1159\/000507638","journal-title":"Psychother Psychosom"},{"key":"939_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/15622975.2017.1285048","volume":"19","author":"M Letmaier","year":"2018","unstructured":"Letmaier\u00a0M, Grohmann\u00a0R, Kren\u00a0C et\u00a0al (2018) Venous thromboembolism during treatment with antipsychotics: results of a\u00a0drug surveillance programme. World J Biol Psychiatry 19:175\u2013186","journal-title":"World J Biol Psychiatry"},{"key":"939_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10787-018-0498-5","volume":"26","author":"A Mascolo","year":"2018","unstructured":"Mascolo\u00a0A, Berrino\u00a0PM, Gareri\u00a0P et\u00a0al (2018) Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a\u00a0review article. Inflammopharmacol 26:1141\u20131149","journal-title":"Inflammopharmacol"},{"issue":"6","key":"939_CR21","doi-asserted-by":"publisher","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","volume":"19","author":"D McGonagle","year":"2020","unstructured":"McGonagle\u00a0D, Sharif\u00a0K, O\u2019Regan\u00a0A et al (2020) The role of cytokines including Interleukin\u20116 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 19(6):102537. https:\/\/doi.org\/10.1016\/j.autrev.2020.102537","journal-title":"Autoimmun Rev"},{"key":"939_CR22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2008.302","volume":"85","author":"ET Morgan","year":"2009","unstructured":"Morgan\u00a0ET (2009) Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85:434\u2013438","journal-title":"Clin Pharmacol Ther"},{"key":"939_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.12898","volume":"138","author":"N Myles","year":"2018","unstructured":"Myles\u00a0N, Myles\u00a0H, Xia\u00a0S et al (2018) Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand 138:101\u2013109","journal-title":"Acta Psychiatr Scand"},{"key":"939_CR24","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/pds.4028","volume":"25","author":"G Nakafero","year":"2016","unstructured":"Nakafero\u00a0G, Sanders\u00a0RD, Nguyen-Van-Tam\u00a0JS et al (2016) The association between benzodiazepines and influenza-like illness-related pneumonia and mortality: a\u00a0survival analysis using UK primary care data. Pharmacoepidemiol Drug Saf 25:1263\u20131273","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"939_CR25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.pharep.2017.12.003","volume":"70","author":"EA Og\u0142odek","year":"2018","unstructured":"Og\u0142odek\u00a0EA, Just\u00a0MJ, Grzesi\u0144ska\u00a0AD et\u00a0al (2018) The impact of antipsychotics as a\u00a0risk factor for thromboembolism. Pharmacol Rep 70:533\u2013539","journal-title":"Pharmacol Rep"},{"key":"939_CR26","doi-asserted-by":"publisher","DOI":"10.1027\/00561-000","volume-title":"Clinical handbook of psychotropic drugs","author":"RM Procyshyn","year":"2019","unstructured":"Procyshyn\u00a0RM, Bezchilbynk-Butler\u00a0KZ, Jeffries\u00a0JJ (2019) Clinical handbook of psychotropic drugs. Hogrefe Publishing, Boston"},{"key":"939_CR27","doi-asserted-by":"publisher","first-page":"200061","DOI":"10.1503\/jpn.200061","volume":"45","author":"D Siskind","year":"2020","unstructured":"Siskind\u00a0D, Honer\u00a0WG, Clark\u00a0S et al (2020) Consensus statement on the use of clozapine during the COVID-19 pandemic. J\u00a0Psychiatry Neurosci 45:200061","journal-title":"J Psychiatry Neurosci"},{"issue":"5","key":"939_CR28","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3390\/ijerph17051729","volume":"17","author":"C Wang","year":"2020","unstructured":"Wang\u00a0C, Pan\u00a0R, Wan\u00a0X et al (2020) Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health 17(5):1729","journal-title":"Int J Environ Res Public Health"},{"key":"939_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22579","author":"CH Yan","year":"2020","unstructured":"Yan\u00a0CH, Faraji\u00a0F, Prajapati\u00a0DP et al (2020) Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol. https:\/\/doi.org\/10.1002\/alr.22579","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-00939-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-020-00939-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-00939-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T19:44:52Z","timestamp":1622576692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-020-00939-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1007\/s00115-020-00939-4","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"2 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Seifert hat an einer Fortbildungsveranstaltung der Firma Otsuka\/Lundbeck teilgenommen. S.\u00a0Toto erhielt Vortragshonorare von Janssen-Cilag, Otsuka\/Lundbeck und Servier und ist Mitglied des Advisory Board von Otsuka und Janssen-Cilag. G.\u00a0Eckermann erhielt finanzielle Unterst\u00fctzung von Aristo Pharma, Axeleris Pharma, Germania Pharmazeutika, Janssen-Cilag, neuraxpharm Arzneimittel, Pfizer Pharma und Servier. J.\u00a0Heck, M.\u00a0Singer, S.\u00a0Bleich und R.\u00a0Grohmann geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}